In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in digital twin technology.

Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

If the future of oncology research is to be inclusive, efficient, and representative, community-based clinical trials must be ...

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A.

The global, randomized IDeate-Esophageal01 study will evaluate ifinatamab deruxtecan, a B7-H3–targeted antibody-drug ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, highlights key findings from ...